Is there a "Trial Effect" on Outcome of Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib?

PURPOSE: Studies suggested the existence of a ‘trial effect', in which for a given treatment, participation in a clinical trial is associated with a better outcome. Sunitinib is a standard treatment for metastatic renal cell carcinoma (mRCC). We aimed to study the effect of clinical trial parti...

Descripción completa

Detalles Bibliográficos
Autores principales: Keizman, Daniel, Rouvinov, Keren, Sella, Avishay, Gottfried, Maya, Maimon, Natalie, Kim, Jenny J., Eisenberger, Mario A., Sinibaldi, Victoria, Peer, Avivit, Carducci, Michael A., Mermershtain, Wilmosh, Leibowitz-amit, Raya, Weitzen, Rony, Berger, Raanan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4720089/
https://www.ncbi.nlm.nih.gov/pubmed/25761478
http://dx.doi.org/10.4143/crt.2014.289

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4720089/
https://www.ncbi.nlm.nih.gov/pubmed/25761478
http://dx.doi.org/10.4143/crt.2014.289

Ejemplares similares